A recent study suggests that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight much more quickly than those who stop traditional diet and exercise regimens.
Research printed in a prominent medical journal shows that while obese individuals frequently drop substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing these treatments need to be informed of the danger of fast rebound weight gain when the medication ends," stated lead investigator Dr. Susan Jebb.
This pace of regain implies a return to starting mass in about 18 months.
Analyzing Therapies
The research, which examined dozens of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with conventional dieting.
The team note that individuals who lose weight through lifestyle changes alone usually have a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Fast Rebound
Nutrition scientists believe the way of the drugs accounts for the accelerated regain.
The injections copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations far above than the body's typical production could lead to the body to produce less of its endogenous hormone, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating a significant risk."
A Chronic Issue?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts contend that, considering the high risk of weight regain, the treatment is often life-long.
This opinion is echoed by pharmaceutical companies, who note that the results "emphasize the chronic character of obesity," comparing it to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the jabs describe a sudden resurgence of cravings.
"It was like something flipping and you're instantly starving," said one woman.
This difficulty is exacerbated if individuals have not developed sustainable dietary or behavioural changes during therapy.
Widespread Use
Survey data suggest that millions of people in the UK have used these injections in the past year, with interest remaining high.
- Adoption is greater among females than males.
- The middle-aged demographic shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone cure and long-term success relies on integrated behavioural support.
